...
首页> 外文期刊>Case Reports in Infectious Diseases >Successful Treatment of High-Level Aminoglycoside-Resistant Enterococcus faecalis Bacteremia in a Preterm Infant with Ampicillin and Cefotaxime
【24h】

Successful Treatment of High-Level Aminoglycoside-Resistant Enterococcus faecalis Bacteremia in a Preterm Infant with Ampicillin and Cefotaxime

机译:氨苄西林和头孢噻肟早产儿成功治疗高水平抗氨基糖苷类粪便肠球菌细菌血症

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Enterococcal bloodstream infections are usually treated with single-agent antibiotics. In persistent infections, synergistic combination therapy is often required with a beta-lactam and an aminoglycoside antibiotic. High-level aminoglycoside-resistant (HLAR) enterococci are increasingly prevalent and preclude the use of this combination. The use of ampicillin with a third-generation cephalosporin to treat endovascular HLAR Enterococcus infections is becoming more established in the adult population; however, the literature on treatment of such infections in children remains scarce. We report a preterm neonate with persistent HLAR Enterococcus faecalis bacteremia from day of life 9 to 17 despite treatment with ampicillin and vancomycin. On day of life 17, antibiotic treatment was switched to ampicillin and cefotaxime, with subsequent clearance of blood cultures on day of life 20. To our knowledge, this is the first report illustrating the use of ampicillin and cefotaxime for an HLAR E. faecalis infection in a neonate.
机译:肠球菌血流感染通常用单药抗生素治疗。在持续性感染中,通常需要使用β-内酰胺和氨基糖苷类抗生素进行协同联合治疗。高水平的氨基糖苷类耐药性(HLAR)肠球菌越来越普遍,因此无法使用这种组合。在成人人群中,将氨苄西林与第三代头孢菌素一起用于治疗血管内HLAR肠球菌感染的方法越来越普遍。然而,关于治疗儿童感染的文献仍然很少。尽管使用氨苄西林和万古霉素治疗,我们仍报告了从生命的9至17天起持续存在HLAR粪肠球菌细菌血症的早产新生儿。在生命第17天,将抗生素治疗改为氨苄西林和头孢噻肟,并在生命第20天随后清除血培养物。据我们所知,这是第一份说明氨苄西林和头孢噻肟用于HLAR粪肠球菌感染的报道。在新生儿中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号